Nkarta, Inc.

Nkarta, Inc. is a clinical-stage biotechnology company founded in 2015 and headquartered in the United States. The company's slogan, "Harnessing the Power of Natural Killer Cells," encapsulates its focus on advancing the development of allogeneic natural killer (NK) cell therapies. Nkarta stands out in the Biotechnology and Health Care sectors, leveraging its cell expansion and cryopreservation platform along with proprietary cell engineering technologies to build a pipeline of cell therapy candidates. The company recently secured a significant $240.00 million Post-IPO Equity investment on 25 March 2024, with prominent investors such as RA Capital Management, OrbiMed, Adage Capital Management, Commodore Capital, Cormorant Asset Management, EcoR1 Capital, Janus Handerson, Ridgeback Capital, Samsara BioCapital, and SR One participating in the funding round. Nkarta's approach revolves around efficient manufacturing processes and engineering strategies to enhance tumor targeting and improve persistence for sustained activity in the body. As the company continues to progress in its clinical-stage development, its innovative technologies and strong investor backing position it as a key player in the burgeoning field of cell therapy. For more information, visit the company’s website at www.nkartatx.com.